Cervical Cancer Treatment in India
Expert cervical cancer treatment in India — radical hysterectomy, concurrent chemoradiation, and brachytherapy. Among the lowest costs globally with excellent outcomes.
Estimated cost: $3,000 – $7,000 · Average stay: 5–10 days
Cervical cancer is the fourth most common cancer in women globally, with approximately 600,000 new cases diagnosed annually. Over 85% of cases occur in low- and middle-income countries, where screening programs are limited. HPV (human papillomavirus) types 16 and 18 cause approximately 70% of cervical cancers, making HPV vaccination a critical prevention strategy.
Treatment of cervical cancer is highly effective when the disease is detected early. Stage I disease — confirmed to the cervix — has a 5-year survival exceeding 90% with surgical or radiotherapy treatment. Even stage II disease has 65–75% 5-year survival with modern concurrent chemoradiation and brachytherapy. The key to optimal outcomes is receiving treatment at an experienced gynecologic oncology center with skilled radical surgeons and a dedicated radiation oncology team.
India is one of the most experienced countries globally in cervical cancer treatment, driven by the high disease burden that has created large patient volumes and deep surgical and radiotherapy expertise. Leading cancer centers such as Tata Memorial Hospital in Mumbai — which treats among the highest volumes of cervical cancer patients in the world — have published outcomes data that compare favorably with international benchmarks.
Gaf Healthcare connects patients with India's most experienced cervical cancer programs, where dedicated gynecologic oncologists and radiation oncologists work together using evidence-based protocols to deliver the best possible outcomes.
Types and Stages of Cervical Cancer
Squamous cell carcinoma accounts for approximately 70% of cervical cancers; adenocarcinoma accounts for 25%. These subtypes are treated similarly but have some differences in radiation sensitivity and patterns of spread.
FIGO staging (2018 revision incorporates imaging and lymph node findings):
- Stage I: Confined to the cervix. 5-year survival: 90–95%.
- Stage IIA: Upper vaginal involvement, no parametrial invasion. 5-year survival: 75–80%.
- Stage IIB: Parametrial involvement. 5-year survival: 65–75%.
- Stage III: Pelvic wall extension, lower vaginal involvement, or hydronephrosis. 5-year survival: 40–55%.
- Stage IVA: Invasion of bladder or rectum. 5-year survival: 22–35%.
- Stage IVB: Distant metastasis. Treatment is palliative.
Treatment allocation: early-stage disease (IA–IB1) can be treated by radical surgery or radical radiotherapy with equivalent cure rates. Locally advanced disease (IB3 and above) is treated with concurrent chemoradiation (cisplatin + external beam radiation) followed by intracavitary brachytherapy.
Who Is a Candidate for Cervical Cancer Treatment?
Surgical candidates: women with stage IA2–IB2 (and selected IIA1) cervical cancer who are medically fit. Radical hysterectomy (type III/Wertheim hysterectomy) with pelvic lymphadenectomy removes the uterus with wide parametrial tissue and upper vagina. Laparoscopic and robotic approaches are performed at experienced centers.
Fertility-sparing surgery: radical trachelectomy (cervical amputation preserving the uterine body) is an option for young women with small stage IA–IB1 tumors (≤2 cm), preserving the ability to carry a pregnancy.
Concurrent chemoradiation candidates: all patients with stage IB3 (tumors >4 cm) and above. Cisplatin (40 mg/m²) given weekly during 5 weeks of external beam radiation, followed by 3–5 fractions of high-dose-rate (HDR) intracavitary brachytherapy. This combination cures the majority of stage IB3–IIB patients and significantly extends survival in stage III–IVA disease.
Advanced/recurrent disease: pembrolizumab + chemotherapy (paclitaxel + cisplatin or paclitaxel + carboplatin) ± bevacizumab is the current first-line standard for metastatic or recurrent cervical cancer, demonstrating improved overall survival.
Cervical Cancer Treatment: Surgery and Chemoradiation
Radical hysterectomy (Wertheim hysterectomy) involves removal of the uterus and cervix with 2–3 cm of parametrial tissue bilaterally, the upper 2–3 cm of vagina, and pelvic lymph nodes. This is the standard surgical treatment for stage IA2–IB2 cervical cancer. Laparoscopic radical hysterectomy is preferred at high-volume centers for its smaller incisions and faster recovery.
Concurrent chemoradiation for locally advanced cervical cancer: 45 Gy of external beam radiation is delivered to the pelvis over 5 weeks (25 fractions), with weekly cisplatin chemotherapy (40 mg/m²) as a radiosensitizer. This is followed by intracavitary HDR brachytherapy — an applicator is placed inside the uterine cavity and vagina and high-dose radiation is delivered precisely to the residual tumor. The total treatment course takes 7–8 weeks.
Advances in brachytherapy: image-guided adaptive brachytherapy (IGABT), guided by MRI, allows highly personalized dose planning that conforms the radiation dose to the tumor while minimizing dose to the bladder and rectum. This has improved local control rates in cervical cancer significantly.
Procedure Steps
- Diagnosis: colposcopy, directed biopsy, and FIGO staging with MRI pelvis + CT chest/abdomen.
- PET-CT for stages IB3 and above to detect nodal and distant metastases.
- Multidisciplinary tumor board review: gynecologic oncologist + radiation oncologist determine surgery vs chemoradiation.
- For surgical candidates: laparoscopic radical hysterectomy with pelvic lymphadenectomy under general anesthesia.
- For chemoradiation candidates: external beam radiation (45 Gy/25 fractions) + weekly cisplatin for 5 weeks.
- Intracavitary HDR brachytherapy: 4–5 fractions delivered over 1–2 weeks, guided by MRI imaging.
- Response assessment: MRI at 3 months; PET-CT at 3–6 months.
- Surveillance: pelvic examination every 3 months; Pap smear from vaginal vault; CT/MRI as clinically indicated.
Cervical Cancer Treatment Approaches
Radical (Wertheim) Hysterectomy
Laparoscopic or open removal of the uterus, cervix, parametria, upper vagina, and pelvic lymph nodes for early-stage cervical cancer. Provides surgical cure in 85–95% of stage I–IIA disease. Laparoscopic approach preferred for reduced blood loss and faster recovery.
Cost: $4,000 – $8,000
Concurrent Chemoradiation
External beam radiation (45 Gy over 5 weeks) combined with weekly cisplatin chemotherapy to sensitize cancer cells to radiation. The standard curative treatment for locally advanced cervical cancer (stage IB3 and above). Equivalent cure rates to surgery for early-stage disease.
Cost: $4,000 – $8,000 (full course)
HDR Intracavitary Brachytherapy
High-dose-rate radiation delivered directly to the tumor through an applicator placed inside the cervix and vagina, following external beam radiation. Critical component of curative chemoradiation. MRI-guided planning maximizes tumor dose while protecting bladder and rectum.
Cost: $1,500 – $3,000 (full course)
Pembrolizumab + Chemotherapy (Metastatic/Recurrent)
PD-1 inhibitor immunotherapy combined with paclitaxel + platinum chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer. The KEYNOTE-826 trial showed improved overall survival with pembrolizumab addition in PD-L1 positive tumors.
Cost: $2,000 – $4,500 per cycle
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $3,000 – $7,000 — Save 70–80%
UAE — $6,000 – $12,000 — Save 55–65%
USA / UK — $20,000 – $60,000+ — Baseline
India is the world's highest-volume country for cervical cancer treatment due to disease burden, and its cancer centers carry deep expertise accumulated over decades. Radical hysterectomy and complete chemoradiation courses in India cost $5,000–$12,000 total — compared to $60,000–$150,000 in the USA. The same cisplatin-based protocols and HDR brachytherapy technology are used.
Recovery & Follow-up
After radical hysterectomy, hospital stay is 4–6 days. Catheter drainage may be needed for 1–2 weeks. Return to full activity takes 6–8 weeks. After chemoradiation and brachytherapy, acute side effects (diarrhea, urinary frequency, fatigue) improve within 2–4 weeks of completing treatment. Long-term radiation effects (vaginal dryness, bladder irritability) are managed with vaginal dilators and supportive care.
Recovery Tips
- Use vaginal dilators regularly after brachytherapy to prevent vaginal stenosis.
- Stay hydrated and eat a low-residue diet during radiation to minimize bowel side effects.
- Complete all brachytherapy sessions — this component is critical to achieving cure.
- Walk daily during and after treatment to maintain strength and reduce fatigue.
- Attend all follow-up colposcopy and imaging appointments — early detection of recurrence is critical.
Risks & Complications
Radical hysterectomy risks include bladder dysfunction (managed with catheter initially), ureterovaginal fistula (rare), lymphedema, and sexual dysfunction. Chemoradiation risks include acute bowel and urinary side effects and long-term radiation proctitis and bladder changes. Cisplatin nephrotoxicity is prevented with aggressive IV hydration. Brachytherapy applicator placement may cause mild discomfort under anesthesia.
Why GAF Healthcare
Gaf Healthcare partners with India's most experienced cervical cancer centers, including institutions that treat hundreds of new cervical cancer cases monthly. We facilitate rapid diagnostic workup, priority tumor board review, and coordination between surgery and radiation oncology departments to ensure seamless treatment delivery for international patients.
Frequently Asked Questions
What is the cure rate for cervical cancer in India?
Stage I: 90–95%, Stage II: 65–80%, Stage III: 40–55%. India's leading centers, particularly Tata Memorial Hospital, publish outcomes data equivalent to international benchmark institutions. The key to good outcomes is receiving treatment from an experienced gynecologic oncology team.
Is surgery or radiotherapy better for early cervical cancer?
For stage IA2–IB2 cervical cancer, surgery (radical hysterectomy) and radiotherapy achieve equivalent cure rates. Surgery is preferred for younger patients who wish to avoid pelvic radiation side effects. Radiotherapy is preferred for medically unfit patients and older women. The choice is made jointly by the patient and the multidisciplinary team.
How many weeks does cervical cancer radiation treatment take?
External beam radiation takes 5 weeks (25 daily fractions). Concurrent weekly cisplatin chemotherapy is given during this period. Brachytherapy adds 1–2 more weeks. Total treatment duration is 7–8 weeks, typically requiring one continuous stay in India.
Can I get HPV vaccination after cervical cancer treatment?
HPV vaccination is not beneficial after a cervical cancer diagnosis, as it prevents new HPV infection but does not treat existing infection or cancer. However, vaccination is strongly recommended for unaffected children and young adults in the patient's family as prevention.
Does cervical cancer treatment affect fertility?
Radical hysterectomy and chemoradiation both eliminate the ability to carry a pregnancy. For selected young women with early stage IA–IB1 tumors, radical trachelectomy preserves the uterus while removing the cervix, allowing future pregnancy — though this option is only available at specialized centers for tumors under 2 cm.